Animal Health

Zealand Pharma's petrelintide shows double-digit weight loss with remarkably few side effects, positioning it to challenge GLP-1 giants in the $100B market.

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?

Advocacy groups demand a congressional audit, alleging the BLM's sales program creates an unregulated pipeline for slaughtering protected wild horses.

Chinese vaccine maker Zhengye Biotechnology has 180 days to save its Nasdaq listing. But the sub-$1 stock price is just a symptom of deeper financial decay.

A year into a landmark partnership with AI firm VetRec, NC State's vet school shows how student-led tech adoption is freeing clinicians for what matters most.

A pharma revolution is brewing for Generalized Anxiety Disorder. As prevalence soars, novel therapies targeting new neural pathways promise to upend the market.

Beyond greenwashing, the animal health giant's latest report reveals a calculated strategy where innovation, philanthropy, and climate action drive market leadership.

The world's largest veterinary conference, VMX 2027, confronts industry burnout with its 'Off the Grid' theme, blending professional renewal with science.

Parnell's new Sevoflurane offering is more than a product line extension; it's a strategic move to become a one-stop-shop for veterinary anesthesia.

The market for T-cell malignancy treatments is set to surpass $1.8B, fueled by a pipeline of innovative drugs aiming to meet vast unmet patient needs.

A $3.1B company's partnership with a local wildlife center is more than charity; it's a blueprint for how corporations are embedding social value into their strategy.

PBI-Gordon's strategic hire of Kent Luther for Pegasus Labs signals a major push in animal health, blending big pharma talent with an employee-owned model.

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

A call for research on vaccine side effects exposes a deeper crisis: the collapse of public trust in science. Can rigorous data heal a polarized nation?

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.

One year after its US launch, Pictor Holdings is gaining traction with a platform that makes complex disease testing fast, cheap, and accessible. But can its unique business model truly scale?

A breakthrough in cardiac fibrosis treatment reveals more than a new drug; it signals a systemic shift. How AI and human 'organoids' are making animal models obsolete.

Petco Love's massive adoption event is more than a feel-good story; it's a calculated response to an economic crisis forcing New Yorkers to surrender pets.

A strategic deal between epiq Animal Health and Vetirus brings a cost-effective regenerative therapy to vets, promising wider access to advanced care.